{"product_id":"cst-52742s","title":"CST,  52742S, FGF Receptor 2IIIb (FPR2-D) Mouse Monoclonal Antibody","description":"Monoclonal Antibody for studying FGFR2 iso3 (FGFR2IIIb). Validated for Western Blotting,IHC Leica Bond,Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, FGF Receptor 2IIIb (FPR2-D) Mouse Monoclonal Antibody (CST #52742) is ready to ship.\n\n\u003cb\u003eProduct Usage Information\u003c\/b\u003e\nWestern Blotting: 1:1000\nIHC Leica Bond: 1:200 - 1:800\n\u003cb\u003eStorage\u003c\/b\u003e\nSupplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg\/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.\n\u003cb\u003eProtocol\u003c\/b\u003e\nAvailable protocols: Western Blotting, IHC Leica Bond\n\u003cb\u003eSpecificity \/ Sensitivity\u003c\/b\u003e\nFGF Receptor 2IIIb (FPR2-D) Mouse Monoclonal Antibody recognizes endogenous levels of total FGFR2 protein. This antibody specifically detects the FGFR2IIIb isoform (UniProt P21802-3).\nSpecies Reactivity: Human\n\u003cb\u003eSource \/ Purification\u003c\/b\u003e\nMonoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues of human FGFR2IIIb protein.\n\u003cb\u003eBackground\u003c\/b\u003e\nFibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family (FGFR1-4) that share between 56 and 71% sequence identity (1). Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues, initiating downstream signaling pathways (2). Mutations in the gene cause syndromes characterized by facial and limb defects, including LADD Syndrome, Crouzon Syndrome, Beare-Stevenson Cutis Gyrata Syndrome, Pfeiffer Syndrome, Apert Syndrome, and Jackson-Weiss Syndrome (3-5). gene amplification and other mutations, as well as altered expression, have been observed in cases of gastric, endometrial, and breast cancer (6). FGFR2 has two primary isoforms, FGFR2IIIc (isoform1, also known as BEK) and FGFR2IIIb (isoform 3, also known as FGFR2b) that are generated through alternative spicing of the third immunoglobulin-like domain crucial for ligand binding. The isoforms differ in tissue distribution and biological activities (7,8). FGFR2IIIb is mainly detected in epithelial cells and can be overexpressed in estrogen receptor-positive breast cancer and gastric cancer (9-11). It preferentially binds to the ligands FGF7, FGF10, and FGF22, with subsequent receptor homodimerization activating downstream signaling pathways including PI3K\/Akt and RAS-MAPK (12-14). When overexpressed, FGFR2IIIb promotes aberrant signaling, leading to tumor cell proliferation (15).\n\u003cb\u003eAlternate Names\u003c\/b\u003e\nbacteria-expressed kinase; BBDS; BEK; BEK fibroblast growth factor receptor; BFR-1; CD332; CEK3; CFD1; ECT1; FGFR-2; FGFR2; FGFR2 iso3; Fibroblast growth factor receptor 2; JWS; K-sam; Keratinocyte growth factor receptor; KGFR; KSAM; protein tyrosine kinase, receptor like 14; TK14; TK25\n\n\u003cb\u003eSpecification\u003c\/b\u003e\n\nREACTIVITY: H\nSENSITIVITY: Endogenous\nMW (kDa): 92, 145\nSource\/Isotype: Mouse IgG2a kappa","brand":"CST","offers":[{"title":"Default Title","offer_id":46799793815721,"sku":"52742S","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/cst-52742s","provider":"Iright","version":"1.0","type":"link"}